TNGX insider filings
Tango Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-19. Screen TNGX transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 7 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 12 legs across 7 filings by 3 insiders — 82,564 shares, $1,938,345 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 8.
- Largest priced transaction: sale of 26,400 shares @ $24.45 ($645,604) by Crystal Adam, filed 2026-10-05.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Crystal Adam — President, R&D | 4 | — | 6 legs · 64,000 sh · $1,501,813 | 8 |
| Newcomb Jessica — Principal Accounting Officer | 2 | — | 5 legs · 15,231 sh · $356,273 | — |
| Ketchum John B — Director | 1 | — | 1 leg · 3,333 sh · $80,259 | — |
Recent insider filings — Tango Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 4 | Ketchum John B — Director | Sale (S): 3,333 @ $24.08 | EDGAR |
| 2026-11-13 | 4 | Crystal Adam — President, R&D | Option exercise (M): 5,000 @ $2.91 · Sale (S): 5,000 @ $25 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-11-04 | 4 | Crystal Adam — President, R&D | Option exercise (M): 5,000 @ $2.91 · Sale (S): 3,900 @ $22.26 · Sale (S): 1,100 @ $22.99 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-11-04 | 4 | Newcomb Jessica — Principal Accounting Officer | Sale (S): 5,571 @ $22.28 · Sale (S): 1,460 @ $22.98 | EDGAR |
| 2026-10-05 | 4 | Crystal Adam — President, R&D | Option exercise (M): 27,000 @ $5.20 · Sale (S): 26,400 @ $24.45 · Sale (S): 600 @ $25.32 · Option exercise (M): 27,000 (derivative) @ $0 | EDGAR |
| 2026-09-24 | 4 | Newcomb Jessica — Principal Accounting Officer | Sale (S): 700 @ $22.80 · Sale (S): 5,100 @ $23.97 · Sale (S): 2,400 @ $25.17 | EDGAR |
| 2026-09-03 | 4 | Crystal Adam — President, R&D | Option exercise (M): 27,000 @ $5.20 · Sale (S): 27,000 @ $22.37 · Option exercise (M): 27,000 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Crystal Adam — President, R&D | Option exercise (M): 27,000 @ $5.20 · Sale (S): 5,267 @ $26.79 · Sale (S): 21,733 @ $27.35 · Option exercise (M): 27,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Crystal Adam — President, R&D | Option exercise (M): 27,000 @ $5.20 · Sale (S): 19,629 @ $29.34 · Sale (S): 7,371 @ $30.25 · Option exercise (M): 27,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Azelby Robert — Director | Grant/award (A): 5,740 @ $0 · Grant/award (A): 35,910 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Ketchum John B — Director | Grant/award (A): 4,000 @ $0 · Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Rothenberg Mace — Director | Grant/award (A): 4,000 @ $0 · Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Lee Sung — Director | Grant/award (A): 570 @ $0 · Grant/award (A): 3,570 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Calhoun Lesley Ann — Director | Grant/award (A): 4,000 @ $0 · Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Crystal Adam — President, R&D | Option exercise (M): 27,000 @ $5.20 · Sale (S): 6,140 @ $22.25 · Sale (S): 20,860 @ $23.06 · Option exercise (M): 27,000 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Crystal Adam — President, R&D | Option exercise (M): 27,000 @ $5.20 · Sale (S): 25,900 @ $21.19 · Sale (S): 1,100 @ $22.00 · Option exercise (M): 27,000 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Gall Matthew — Chief Financial Officer | Grant/award (A): 40,000 @ $0 · Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Lee Sung — Director | Grant/award (A): 12,300 @ $0 · Grant/award (A): 5,200 (derivative) @ $0 | EDGAR |
| 2026-04-16 | 4 | Crystal Adam — President, R&D | Option exercise (M): 38,460 @ $5.20 · Sale (S): 38,460 @ $25 · Option exercise (M): 38,460 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Crystal Adam — President, R&D | Option exercise (M): 27,000 @ $5.20 · Sale (S): 27,000 @ $21.20 · Option exercise (M): 27,000 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | Crystal Adam — President, R&D | Option exercise (M): 12,000 @ $5.20 · Sale (S): 12,000 @ $20.11 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Crystal Adam — President, R&D | Sale (S): 20,251 @ $15 | EDGAR |
| 2026-02-27 | 4 | Crystal Adam — President, R&D | Sale (S): 54,345 @ $12.77 | EDGAR |
| 2026-02-04 | 4 | Crystal Adam — President, R&D | Grant/award (A): 47,460 @ $0 · Sale (S): 18,251 @ $12.26 · Sale (S): 201 @ $12.90 · Grant/award (A): 284,760 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Weber Barbara — Director, Executive Chair, Director | Grant/award (A): 37,522 @ $0 · Sale (S): 30,186 @ $12.26 · Sale (S): 333 @ $12.90 · Grant/award (A): 222,132 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Beckman Daniella — Chief Financial Officer | Grant/award (A): 44,330 @ $0 · Sale (S): 10,204 @ $12.26 · Sale (S): 113 @ $12.90 · Grant/award (A): 265,980 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Peters Malte — President & CEO, Director | Grant/award (A): 350,000 @ $0 · Grant/award (A): 1,650,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Lee Sung — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-11-04 | 4 | Peters Malte — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | Third Rock Ventures IV, L.P. — 10% owner Third Rock Ventures GP IV, L.P. — 10% owner TRV GP IV, LLC — 10% owner | Sale (S): 477,401 @ $10.15 | EDGAR |
| 2025-09-29 | 4 | Third Rock Ventures IV, L.P. — 10% owner Third Rock Ventures GP IV, L.P. — 10% owner TRV GP IV, LLC — 10% owner | Sale (S): 500,000 @ $8.02 | EDGAR |
| 2025-09-17 | 4 | Third Rock Ventures IV, L.P. — 10% owner Third Rock Ventures GP IV, L.P. — 10% owner TRV GP IV, LLC — 10% owner | Sale (S): 363,541 @ $7.04 | EDGAR |
| 2025-09-09 | 4 | Third Rock Ventures IV, L.P. — 10% owner Third Rock Ventures GP IV, L.P. — 10% owner TRV GP IV, LLC — 10% owner | Sale (S): 642,906 @ $7 · Sale (S): 86,459 @ $7.04 | EDGAR |
| 2025-08-26 | 4 | Third Rock Ventures IV, L.P. — 10% owner Third Rock Ventures GP IV, L.P. — 10% owner TRV GP IV, LLC — 10% owner | Sale (S): 302,194 @ $7 | EDGAR |
| 2025-08-21 | 4 | Third Rock Ventures IV, L.P. — 10% owner Third Rock Ventures GP IV, L.P. — 10% owner TRV GP IV, LLC — 10% owner | Sale (S): 1,100,000 @ $7.01 | EDGAR |
| 2025-06-09 | 4 | Peters Malte — Director | Grant/award (A): 6,250 @ $0 · Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Rothenberg Mace — Director | Grant/award (A): 6,250 @ $0 · Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Ketchum John B — Director | Grant/award (A): 6,250 @ $0 · Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Calhoun Lesley Ann — Director | Grant/award (A): 6,250 @ $0 · Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Borisy Alexis — Director | Grant/award (A): 6,250 @ $0 · Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Barry Douglas — General Counsel | Sale (S): 2,774 @ $2.99 · Sale (S): 2,556 @ $3.16 | EDGAR |
| 2025-02-06 | 4 | Crystal Adam — See Remarks | Sale (S): 7,432 @ $2.99 · Sale (S): 6,851 @ $3.16 | EDGAR |
| 2025-02-06 | 4 | Weber Barbara — Chief Executive Officer, Director | Sale (S): 9,778 @ $2.99 · Sale (S): 9,013 @ $3.16 | EDGAR |
| 2025-02-06 | 4 | Beckman Daniella — Chief Financial Officer | Sale (S): 4,284 @ $2.99 · Sale (S): 3,948 @ $3.16 | EDGAR |
| 2025-02-05 | 4 | Crystal Adam — See Remarks | Grant/award (A): 53,015 @ $0 · Grant/award (A): 318,090 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Barry Douglas — General Counsel | Grant/award (A): 27,363 @ $0 · Grant/award (A): 164,175 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Weber Barbara — Chief Executive Officer, Director | Grant/award (A): 105,875 @ $0 · Grant/award (A): 635,250 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Beckman Daniella — Chief Financial Officer | Grant/award (A): 26,119 @ $0 · Grant/award (A): 156,713 (derivative) @ $0 | EDGAR |
| 2024-11-18 | 4 | Rothenberg Mace — Director | Purchase (P): 10,000 @ $3.62 · Purchase (P): 10,000 @ $3.78 | EDGAR |
| 2024-11-08 | 4 | EcoR1 Capital, LLC — 10% owner | Sale (S): 1,494,558 @ $3.28 · Sale (S): 62,318 @ $3.29 · Sale (S): 1,143,124 @ $2.92 | EDGAR |
Recent 8-K events — Tango Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-23 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-07 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-08 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TNGX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs